Entrada Therapeutics TRDA Cash Flow Statement (2020-2026)

NASDAQ TRDA
$5.44 +0.19 (+3.62%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Entrada Therapeutics Quarterly Cash Flow Statement

Periods 25 quarters
Latest Sep 2026

Entrada Therapeutics reported cash from operations of -$29.96M and free cash flow of -$30.12M for the quarter ended Sep 2026, down 5.8% year over year. This cash flow statement covers 25 quarters of results from Sep 2020 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-18.49M-21.67M-23.18M-25.14M-24.63M-6.67M-25.93M35.46M-9.54M23.50M55.03M-14.03M1.13M-17.35M-43.10M-44.13M-39.16M-39.72M-42.76M-39.74M
Depreciation and DepletionDep. & Depletion
0.32M0.40M0.50M0.50M0.50M0.54M0.70M0.80M0.74M0.93M0.90M0.90M1.00M0.95M1.10M1.20M0.89M0.81M0.80M0.70M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.14M0.15M-0.03M-0.10M-0.24M
Depreciation & Amortization (CF)Dep. & Amort.
0.32M0.40M0.50M0.50M0.50M0.54M0.70M0.80M0.74M0.93M0.90M0.90M1.00M0.95M1.10M1.20M0.89M0.81M0.80M0.70M
Share-based CompensationStock Comp.
1.46M1.79M2.51M2.71M2.88M2.76M3.12M3.40M3.84M3.73M4.62M4.86M4.70M5.09M5.05M5.12M4.36M4.74M5.15M4.78M
Gains from Sales and DivestituresGains Divest
0.08M0.00M0.00M
Change in Working Capital
Change in ReceivablesChange Receivables
-6.30M2.55M-1.28M-0.85M-71.64M69.84M5.07M-1.08M1.64M0.86M-0.02M0.02M0.39M-0.03M-0.02M
Change in Account PayablesChange Payables
-1.03M2.06M1.54M-2.91M4.59M0.53M-4.38M-1.37M2.41M-0.66M-0.89M-0.31M2.85M-1.91M-0.32M1.31M-0.88M0.64M0.82M1.12M
Change in Accrued ExpensesChange Accrued Exp.
1.82M-1.53M0.73M6.90M-4.34M4.11M-5.05M2.80M1.96M-2.52M1.62M3.04M-0.43M-5.46M4.31M3.74M2.15M-5.95M1.27M3.28M
Change in TaxesChange Taxes
7.36M-7.36M4.02M1.83M-1.74M-1.86M-1.58M0.14M-0.80M0.62M-0.62M
Change in Other Operating AssetsOther Assets Change
4.69M0.65M-1.73M7.57M4.22M7.26M-11.97M14.24M-12.70M66.40M-71.56M-6.41M0.94M-2.11M-8.33M-7.31M-3.29M0.40M-3.96M-1.50M
Change in Other Operating LiabilitiesOther Liabilities Change
0.06M-1.53M-1.94M-1.96M-2.01M209.63M-21.22M-42.17M-18.13M16.10M-89.01M-20.10M-35.82M-20.72M-3.02M-2.76M-1.59M-1.27M-1.29M-1.31M
Other Working Capital ChangesOther WC Changes
-4.64M-2.18M-0.22M-9.53M-6.23M202.37M-9.25M-56.41M-5.43M-50.30M-17.46M-13.68M-36.76M-18.62M5.30M4.55M1.70M-1.67M2.67M0.19M
Cash from OperationsCash from Ops.
-20.54M-20.99M-18.01M-27.48M-27.30M203.40M-35.09M-24.49M-4.01M-25.52M39.83M-24.27M-31.61M-38.51M-29.49M-28.31M-32.20M-41.70M-32.46M-29.96M
Investing Activities
Capital ExpendituresCapex
1.32M0.59M0.78M0.81M0.71M1.67M1.52M1.45M0.98M0.84M1.05M0.64M0.64M1.14M0.28M-0.17M-0.21M0.04M0.01M0.16M
Change in Property, Plant and EquipmentChange in PP&E
-1.32M-0.59M-0.78M-0.81M-0.71M-1.67M-1.52M-1.45M-0.98M-0.84M-1.05M-0.64M-0.64M-1.14M-0.28M0.17M0.21M-0.04M-0.01M-0.16M
Purchase of InvestmentsInvestments Purchased
182.65M39.32M101.78M140.12M76.79M88.52M96.94M110.69M165.59M64.50M80.02M16.55M26.57M18.47M11.83M3.93M7.92M
Sale and Maturity of InvestmentsInvestments Sold
1.71M25.00M30.00M19.50M63.00M28.39M74.50M108.54M123.92M87.36M83.31M118.50M85.95M50.63M75.50M47.39M38.86M58.89M51.00M
Cash from Investing ActivitiesCash from Investing
-1.32M-181.53M24.23M-10.13M18.79M-40.44M-113.26M-3.74M19.04M26.15M-24.38M-82.93M53.37M4.78M33.80M49.11M29.12M26.99M54.95M42.92M
Financing Activities
Change in Capital Stock
Common Stock IssuedStock Issued
190.76M0.05M0.01M0.06M0.36M19.54M-18.96M0.37M0.69M0.21M101.37M-0.01M-98.21M0.35M0.34M0.01M0.19M0.10M0.35M
Net Shares Issued and RepurchasedNet Shares Issued
190.76M0.05M0.01M0.06M0.36M19.54M-18.96M0.37M0.69M0.21M101.37M-0.01M-98.21M0.35M0.34M0.01M0.19M0.10M0.35M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
190.76M0.05M0.01M0.06M0.36M19.54M-18.96M0.37M0.69M0.21M101.37M-0.01M-98.21M0.35M0.34M0.01M0.19M0.10M0.35M
Cash from Financing ActivitiesCash from Financing
190.76M0.05M0.01M0.06M0.36M19.54M0.44M0.37M0.69M0.21M101.37M-0.01M1.40M0.35M0.34M0.01M0.19M0.10M0.35M
Additional items
Change in Cash
168.89M-202.47M6.23M-37.56M-8.15M182.49M-147.91M-27.86M15.72M0.83M116.82M-107.20M23.16M-33.37M4.65M20.80M-2.89M-14.61M22.84M12.96M
Ending Cash Balance
291.06M88.59M94.82M57.26M49.11M231.60M83.69M55.83M71.55M72.39M189.20M82.00M105.16M71.79M76.43M97.24M94.34M79.74M102.57M115.53M
Free Cash FlowFCF
-21.86M-21.59M-18.78M-28.29M-28.01M201.73M-36.61M-25.94M-4.99M-26.36M38.79M-24.91M-32.24M-39.65M-29.76M-28.14M-32.00M-41.74M-32.47M-30.13M
Net Cash FlowNCF
168.89M-202.47M6.23M-37.56M-8.15M182.49M-147.91M-27.86M15.72M0.83M116.82M-107.20M23.16M-33.37M4.65M20.80M-2.89M-14.61M22.84M12.96M
Income Taxes PaidTaxes Paid
32.99M-32.99M-62.87M

Entrada Therapeutics Cash Flow Statement API

Pull Entrada Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=TRDA&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY